PDB: 2356 resultsInfo pagesStatus searchChemie searchBIRD

---

3AC3	Crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394) Descriptor: 2-[(3,5-dimethoxyphenyl)amino]-5-ethyl-7-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide, Proto-oncogene tyrosine-protein kinase LCK, SULFATE ION Authors: Tsuji, E. Deposit date: 2009-12-28 Release date: 2010-06-30 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2.55 Å) Cite: Ab initio fragment molecular orbital study of ligand binding to leukocyte-specific protein tyrosine (LCK) kinase To be Published
3AC2	Crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394) Descriptor: (4S)-2-METHYL-2,4-PENTANEDIOL, 7-[(2-amino-2-methylpropyl)amino]-2-[(3,5-dimethoxyphenyl)amino]-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide, DIMETHYL SULFOXIDE, ... Authors: Tsuji, E. Deposit date: 2009-12-28 Release date: 2010-06-30 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2.1 Å) Cite: Ab initio fragment molecular orbital study of ligand binding to leukocyte-specific protein tyrosine (LCK) kinase To be Published
3AC1	Crystal structure of pyrazin derivative bound to the kinase domain of Human LCK, (Auto-phosphorylated on TYR394) Descriptor: (4S)-2-METHYL-2,4-PENTANEDIOL, 5-{[(1R,2S)-2-aminocyclohexyl]amino}-3-[(3,5-dimethoxyphenyl)amino]pyrazine-2-carboxamide, DIMETHYL SULFOXIDE, ... Authors: Tsuji, E. Deposit date: 2009-12-28 Release date: 2010-06-30 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (1.99 Å) Cite: Ab initio fragment molecular orbital study of ligand binding to leukocyte-specific protein tyrosine (LCK) kinase To be Published
3A4P	human c-MET kinase domain complexed with 6-benzyloxyquinoline inhibitor Descriptor: (2E)-3-{6-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]quinolin-3-yl}-N-methylprop-2-enamide, CHLORIDE ION, Hepatocyte growth factor receptor, ... Authors: Fukami, T.A, Kadono, S, Yamamuro, M, Matsuura, T. Deposit date: 2009-07-13 Release date: 2010-02-16 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (2.54 Å) Cite: Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors Bioorg.Med.Chem.Lett., 20, 2010
3A4O	Lyn kinase domain Descriptor: STAUROSPORINE, Tyrosine-protein kinase Lyn Authors: Miyano, N, Kinoshita, T, Tada, T. Deposit date: 2009-07-11 Release date: 2009-12-08 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (3 Å) Cite: Structural basis for the inhibitor recognition of human Lyn kinase domain Bioorg.Med.Chem.Lett., 19, 2009
2ZYB	Crystal structure of phenylimidazo pyrazin 2 bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394) Descriptor: N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine, Proto-oncogene tyrosine-protein kinase LCK, SULFATE ION Authors: Tsuji, E. Deposit date: 2009-01-19 Release date: 2009-02-03 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2.55 Å) Cite: The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase Bioorg.Med.Chem., 16, 2008
2ZVA	Lyn Tyrosine Kinase Domain-Dasatinib complex Descriptor: N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE, Tyrosine-protein kinase Lyn Authors: Williams, N.K, Rossjohn, J. Deposit date: 2008-11-04 Release date: 2008-11-11 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (2.6 Å) Cite: Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State J.Biol.Chem., 284, 2009
2ZV9	Lyn Tyrosine Kinase Domain-PP2 complex Descriptor: 1-TERT-BUTYL-3-(4-CHLORO-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YLAMINE, Tyrosine-protein kinase Lyn Authors: Williams, N.K, Rossjohn, J. Deposit date: 2008-11-04 Release date: 2008-11-11 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (2.76 Å) Cite: Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State J.Biol.Chem., 284, 2009
2ZV8	Lyn Tyrosine Kinase Domain-AMP-PNP complex Descriptor: PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER, Tyrosine-protein kinase Lyn Authors: Williams, N.K, Rossjohn, J. Deposit date: 2008-11-04 Release date: 2008-11-11 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (2.7 Å) Cite: Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State J.Biol.Chem., 284, 2009
2ZV7	Lyn Tyrosine Kinase Domain, apo form Descriptor: Tyrosine-protein kinase Lyn Authors: Williams, N.K, Rossjohn, J. Deposit date: 2008-11-04 Release date: 2008-11-11 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (2.5 Å) Cite: Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State J.Biol.Chem., 284, 2009
2ZM4	Crystal structure of imidazo quinoxaline 1 bound to the kinase domain of human LCK, activated form (auto-phosphorylated on TYR394) Descriptor: DIMETHYL SULFOXIDE, N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine, Proto-oncogene tyrosine-protein kinase LCK, ... Authors: Tsuji, E. Deposit date: 2008-04-11 Release date: 2008-10-14 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2.7 Å) Cite: The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase Bioorg.Med.Chem., 16, 2008
2ZM3	Complex Structure of Insulin-like Growth Factor Receptor and Isoquinolinedione Inhibitor Descriptor: (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione, Insulin-like growth factor 1 receptor Authors: Xu, W, Mayer, S.C, Boschelli, F, Johnson, M, Dwyer, B. Deposit date: 2008-04-10 Release date: 2008-06-10 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2.5 Å) Cite: Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment Bioorg.Med.Chem.Lett., 18, 2008
2ZM1	Crystal structure of imidazo pyrazin 1 bound to the kinase domain of human LCK, (auto-phosphorylated on TYR394) Descriptor: DIMETHYL SULFOXIDE, N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine, Proto-oncogene tyrosine-protein kinase LCK, ... Authors: Tsuji, E. Deposit date: 2008-04-10 Release date: 2008-10-14 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2.1 Å) Cite: The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase Bioorg.Med.Chem., 16, 2008
2Z8C	Phosphorylated insulin receptor tyrosine kinase in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin-2-yl]amino}phenyl)acetic acid Descriptor: 6-mer peptide from Insulin receptor substrate 1, Insulin receptor, [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Authors: Katayama, N, Kurihara, H. Deposit date: 2007-09-05 Release date: 2008-08-12 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (3.25 Å) Cite: Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors. Proteins, 73, 2008
2Z60	Crystal Structure of the T315I Mutant of Abl kinase bound with PPY-A Descriptor: 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE, Proto-oncogene tyrosine-protein kinase ABL1 Authors: Zhou, T, Dalgarno, D, Zhu, X. Deposit date: 2007-07-21 Release date: 2007-09-18 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (1.95 Å) Cite: Crystal Structure of the T315I Mutant of Abl Kinase Chem.Biol.Drug Des., 70, 2007
2YN8	ephB4 kinase domain inhibitor complex Descriptor: EPHRIN TYPE-B RECEPTOR 4, STAUROSPORINE Authors: Read, J, Brassington, C.A, Overmann, R. Deposit date: 2012-10-13 Release date: 2013-10-23 Last modified: 2024-05-08 Method: X-RAY DIFFRACTION (2.11 Å) Cite: Stability and Solubility Engineering of the Ephb4 Tyrosine Kinase Catalytic Domain Using a Rationally Designed Synthetic Library. Protein Eng.Des.Sel., 26, 2013
2YJS	Structure of C1156Y Mutant Anaplastic Lymphoma Kinase Descriptor: ALK TYROSINE KINASE RECEPTOR Authors: McTigue, M, Deng, Y, Liu, W, Brooun, A. Deposit date: 2011-05-23 Release date: 2012-06-06 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (1.9 Å) Cite: Structure of C1156Y Mutant Anaplastic Lymphoma Kinase To be Published
2YJR	Structure of F1174L Mutant Anaplastic Lymphoma Kinase Descriptor: ALK TYROSINE KINASE RECEPTOR Authors: McTigue, M, Deng, Y, Liu, W, Brooun, A. Deposit date: 2011-05-23 Release date: 2012-06-06 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (1.9 Å) Cite: Structure of F1174L Mutant Anaplastic Lymphoma Kinase To be Published
2YIY	Crystal structure of compound 8 bound to TAK1-TAB Descriptor: (1E)-1-[5-TERT-BUTYL-2-(3-FLUOROPHENYL)-1H-PYRAZOL-3-YLIDENE]-3-(4-PYRIDIN-3-YLOXYPHENYL)UREA, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 Authors: Brown, D.G, Phillips, C. Deposit date: 2011-05-17 Release date: 2012-05-23 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (2.49 Å) Cite: The Discovery and Synthesis of Selective Dfg-Out Tak-1 Inhibitors To be Published
2YHV	Structure of L1196M Mutant Anaplastic Lymphoma Kinase Descriptor: ALK TYROSINE KINASE RECEPTOR Authors: McTigue, M, Deng, Y, Liu, W, Brooun, A. Deposit date: 2011-05-06 Release date: 2011-05-18 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (1.9 Å) Cite: Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib. J.Med.Chem., 57, 2014
2YFX	Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib Descriptor: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine, TYROSINE-PROTEIN KINASE RECEPTOR Authors: McTigue, M, Deng, Y, Liu, W, Brooun, A. Deposit date: 2011-04-08 Release date: 2011-05-04 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (1.7 Å) Cite: Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib. J.Med.Chem., 57, 2014
2Y6O	Crystal structure of EphA4 kinase domain in complex with Dasatinib. Descriptor: EPHRIN TYPE-A RECEPTOR 4, N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE Authors: Farenc, C.J.A, Celie, P.H.N, Siegal, G. Deposit date: 2011-01-25 Release date: 2011-11-02 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (1.543 Å) Cite: Crystal Structure of the Epha4 Protein Tyrosine Kinase Domain in the Apo- and Dasatinib-Bound State. FEBS Lett., 585, 2011
2Y6M	Crystal structure of EphA4 kinase domain Descriptor: EPHRIN TYPE-A RECEPTOR 4, GLYCEROL Authors: Farenc, C.J.A, Celie, P.H.N, Siegal, G. Deposit date: 2011-01-25 Release date: 2011-11-02 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (1.7 Å) Cite: Crystal Structure of the Epha4 Protein Tyrosine Kinase Domain in the Apo- and Dasatinib-Bound State. FEBS Lett., 585, 2011
2Y4I	KSR2-MEK1 heterodimer Descriptor: ADENOSINE-5'-TRIPHOSPHATE, CHLORIDE ION, DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1, ... Authors: Brennan, D.F, Barford, D. Deposit date: 2011-01-06 Release date: 2011-01-19 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (3.46 Å) Cite: A Raf-Induced Allosteric Transition of Ksr Stimulates Ksr and Raf Phosphorylation of Mek Nature, 472, 2011
2XYU	Crystal structure of EphA4 kinase domain in complex with VUF 12058 Descriptor: 5-(5-FLUORO-2-METHYLPHENYL)-6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[3,4-C]ISOQUINOLIN-1-AMINE, EPHRIN TYPE-A RECEPTOR 4,, GLYCEROL Authors: Farenc, C.J.A, Celie, P.H.N, vanLinden, O.P.J, Siegal, G. Deposit date: 2010-11-19 Release date: 2011-11-30 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (2.117 Å) Cite: Fragment Based Lead Discovery of Small Molecule Inhibitors for the Epha4 Receptor Tyrosine Kinase. Eur.J.Med.Chem., 47, 2012

<78798081828384858687888990919293>